Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ABCC1
REST API REST API
Homo sapiens
ABCC1 is differentially expressed in 317 experiments: 156 organism parts: liver, testis, ... (154 more);, 187 disease states: normal, prostate carcinoma, ... (185 more);, 89 cell types 395 cell lines 45 compound treatments and 74 other conditions.
Synonyms MRP, GS-X, MRP1
Orthologs F1MY01_BOVIN (Bos taurus)   Abcc1 (Mus musculus)   ABCC1 (Danio rerio)   YCF1 (Saccharomyces cerevisiae)   MRP (Drosophila melanogaster)   LOC688708 (Rattus norvegicus)   abcc1 (Xenopus laevis)   MRP1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transporter activity, plasma membrane, transport, leukotriene biosynthetic process, nucleoside-triphosphatase activity, ATPase activity, Golgi apparatus, membrane fraction, ATP binding, ATPase activity, coupled to transmembrane movement of substances, integral to plasma membrane, nucleus, nucleotide binding, response to drug, integral to membrane, hydrolase activity, transmembrane transport, ATP catabolic process, prostanoid metabolic process
InterPro Term ATPase_AAA+_core, ABC_transporter-like, Multidrug-R_assoc, ABC_transptr_TM_dom, ABC_transporter_type1
UniProt Accession P33527, Q9BV39, F5GXL7
Search EB-eye ENSG00000103222
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
1
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
Jurkat
2
E-MTAB-62, E-MEXP-2197
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
389 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (46 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
whole blood
2
E-GEOD-3026, E-MTAB-25
monocyte
2
3
E-GEOD-22373, E-GEOD-11755, E-GEOD-5099, E-GEOD-995, E-MEXP-583 ... (5 experiments)
mononuclear cell
1
E-GEOD-6053
intraepithelial cytotoxic T lymphocyte
1
E-GEOD-4592
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (63 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-MTAB-62, E-MEXP-2034, E-MEXP-1327, E-GEOD-96, E-GEOD-7307 ... (5 experiments)
uterine fibroid
3
E-GEOD-2724, E-GEOD-7307, E-MTAB-62
glioblastoma
1
3
E-GEOD-4290, E-MTAB-62, E-GEOD-6014, E-GEOD-4412
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
181 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-GEOD-1417, E-GEOD-3720, ... (30 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
estradiol
1
E-GEOD-20081
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
Cxcl12
1
E-GEOD-7307
phoshate buffered saline
1
E-GEOD-3720
M-CSF
1
E-GEOD-5099
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-994, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147, E-GEOD-21887

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (38 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-MEXP-1082, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-GEOD-2487 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-12293, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.416 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM